Why the study?
Do specific antihypertensive monotherapies reduce blood pressure differentially based on clinical, laboratory, and genetic predictors in men with essential hypertension?
Do specific antihypertensive monotherapies reduce blood pressure differentially based on clinical, laboratory, and genetic predictors in men with essential hypertension?
Baseline clinical factors (like plasma renin activity) and genetic variants (like STK39) may help individualize antihypertensive therapy by predicting blood pressure responses to specific drug classes.
No takes yet. Share an insight, caveat, or question.
May guide initial monotherapy selection by renin activity and STK39 status; extends precision-medicine evidence from prior observational data.
Hiltunen et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: